Dataset Information

Multiomics dissection of the BRAF V600E mutation-induced cellular state transition in the lung epithelial cells

ABSTRACT: Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, and 4% of NSCLC patients are reported to harbor mutations in BRAF, which encodes a serine/threonine kinase capable of activating the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. However, the role and effect of BRAF mutation in NSCLC or lung lineage cells are not fully understood. To mimic the naturally occurring BRAF V600E mutation in lung cancer, a BRAF V600E knock-in BEAS-2B cell model was established using CRISPR/Cas9. The cancer cell biology of the BRAF V600E knock-in BEAS-2B cell was characterized by CCK8 assay, colony formation assay and Transwell assay. The proteomics and untargeted metabolomics were carried out to evaluate the underlying changes at the proteome and metabolome levels, respectively. The levels of specific proteins were examined by Western blotting. Although the BRAF V600E mutation alone was not sufficient to drive lung carcinogenesis, it induced remarkable changes in cellular migration capacity and tumorigenic potential. Proteomics analysis revealed significant changes in the proteins involved in the biological processes including epithelial-mesenchymal transition (EMT), extracellular matrix (ECM)-receptor interaction, cell adhesion, focal adhesion, and cell metabolism upon BRAF V600E mutation. Untargeted metabolomics experiments revealed that amino acid metabolism, especially the glycine, serine and threonine metabolism, was significantly modulated in BRAF V600E knock-in cells. In summary, our present study provides a new isogenic cell model that allows us to systematically dissect the underlying molecular events involved in the transition of cellular states upon the introduction of the BRAF V600E mutation.

ORGANISM(S): Homo Sapiens

SUBMITTER: Lingyun Dai

PROVIDER: PXD076776 | iProX | Wed Apr 08 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Similar Datasets

Project description:The success of targeted therapies creates a need to discriminate tumors accurately by their histological and genetic characteristics. Here, we used cDNA microarray analysis to identify gene expression profiles and single markers that recapitulate the pathological and genetic background (i.e., BRAF, EGFR, KRAS, LKB1, PIK3CA, and TP53 gene alterations) of non-small cell lung cancer (NSCLC). Gene expression profiles were determined for 6 normal lung tissues and 69 lung tumors from patients diagnosed with NSCLC. We performed an unsupervised hierarchical clustering with the most variably expressed transcript to investigate whether there was evidence for natural grouping samples based on similarity in gene expression profiles. We examined the relationship between the clusters of tumors and patient and tumor characteristics such as gender, smoking status, histological type, degree of differentiation, tumor size, lymph node involvement and genetic background. We used a supervised analysis to identify the genes that are important for distinguishing subgroups of tumors defined by histological type. Moreover, we used this supervised approach to search for markers that characterize those tumors carrying EGFR, KRAS, PIK3CA and TP53 alterations. We identify several genes with characteristic patterns of expression in each tumor histological type (adenocarcinoma and squamous cell carcinoma) and we found that the presence of EGFR mutations result in a particular expression profile. Keywords: Transciption profiling of tumors with different histological and genetic background. We analyzed 69 NSCLC tumors. All the samples were characterized by histological type and by the presence of alterations at genes that are known to be involved in lung carcinogenesis. Mutational analysis of BRAF, EGFR, KRAS, and LKB1 is provided only for adenocarcinomas and analysis of alterations at PIK3CA gene (mutational analysis or gene amplification by FISH analysis) is provided only for 47 of the tumors. We analyzed gene expression profiles to identify those genes that are differentially expressed between two subgroups by t-test: 1) adenocarcinomas vs. squamous cell carcinomas; 2) tumors with mutation at EGFR gene vs. wild type tumors; 3) tumors with mutation at KRAS gene vs. wild type tumors; 4) tumors with mutation at TP53 gene vs. wild type tumors; 5) tumors with alterations (mutation or gene amplification) at PIK3CA gene vs. wild type tumors.

Dataset Information

Multiomics dissection of the BRAF V600E mutation-induced cellular state transition in the lung epithelial cells

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets